Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at

Upcoming Events

Aug 5, 2014
8:30 AM ET
Webcast Regeneron Pharmaceuticals Q2 2014 Earnings Conference Call

View all releases Recent Press Releases

Jul 18, 2014 Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Jul 18, 2014 Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Jun 27, 2014 EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Jun 12, 2014 Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
Jun 11, 2014 EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Jun 2, 2014 Regeneron Announces Winners of the 2014 Regeneron Prize for Creative Innovation
May 30, 2014 Regeneron Announces Update to Upcoming 2014 Investor Conference Presentations
May 8, 2014 Regeneron Reports First Quarter 2014 Financial and Operating Results
May 5, 2014 Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology

Form content here please :)